Vaccinex Announces Full Enrollment Achieved in Ongoing CLASSICAL-Lung Phase 1b/2 Trial of Pepinemab in Combination with BAVENCIO® (avelumab) in Advanced Non-Small Cell Lung Cancer

    NEXT STORY
    Global Pediatric Vaccine Market Will Reach to USD 56.28 Billion By 2025: Zion Market Research
    PREV STORY
    iTeos Therapeutics Announces Appointment of Matthew Call as Chief Operating Officer
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Innovation Pharmaceuticals Reports p53 Drug Candidate Therapeutic Potential Further Supported by Academic Research in Leukemias and in Combination with Cancer Immunotherapies

    author_avatar
    NASDAQ Market News

    Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial

    CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset ...

    author_avatar
    NASDAQ Market News

    Biocartis Group NV: Biocartis and Amgen Sign New Companion Diagnostic Agreement for Novel Oncology Compound

    PRESS RELEASE: 9 January 2018, 07:01 CET   Biocartis and Amgen Sign New Companion Diagnostic ...

    author_avatar
    NASDAQ Market News